REGN

Regeneron Pharmaceuticals
Biotechnology · Health Care · as of 2026-11-20
Last close
$928.23
+0.6% on the session
1-year return
+32.9%
+45.6% over six months
Volatility
33.9%
annualized, trailing year
Max drawdown
-25.9%
worst peak to trough, 1y
What the numbers say

Regeneron Pharmaceuticals is a biotechnology name in the health care sector. Over the past year it returned +32.9%, against +12.2% over three months and +13.4% over one. It trades 23.8% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 33.9% is above the market's typical range.

Its worst peak-to-trough decline over the year was -25.9%, and it has traded a median $516M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.16 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#15 of 59
Stronger than 76% of its sector on the momentum profile
Across the whole index#44 of 497

How REGN scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day+0.6%
1 week-2.8%
1 month+13.4%
3 months+12.2%
6 months+45.6%
1 year+32.9%
12-1 momentum+17.2%
Volatility (1y, annualized)33.9%
Max drawdown (1y)-25.9%
Distance vs 200-day average+23.8%
Return per unit of risk0.97
Median daily dollar volume$516M
Free newsletter

Get REGN when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.